NCT07737990Enrolling by invitation
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
Psilocybin-assisted psychotherapy requires a lot of resources, with more psychotherapy being provided to integrate the meanings and insights derived from the psilocybin dosing sessions. If group integration therapy is beneficial, then it has the potential to reduce resources required per patient for psilocybin-assisted psychotherapy, thereby increasing the cost-effectiveness of the treatment. However, no research has been done to understand if and how group therapy can support psychedelic integration for people with mood disorders. Therefore, the purpose of this study is to explore the benefit of psilocybin-assisted group therapy and to determine if psychedelic group integration therapy is acceptable to people who have received psychedelic-assisted therapy for mood disorders.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- First submitted
- 27 Jul 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Joshua Rosenblat
- Diseases
- Depression
- NCT number
- NCT07737990
What you commit to
- Study type: Interventional
- Planned participants: 65
- From 1 Jul 2026 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any behaviors that, in the opinion of the investigator, may interfere with the group therapy model (e.g., participants in acute crisis, demonstrated resistance to the therapeutic process of the main clinical trials, etc.);
- Participants who are actively receiving psilocybin-assisted group integration psychotherapy outside of the study.
Other
- Active suicidal ideation as determined by the C-SSRS and/or clinical interview (significant suicide risk is defined by suicidal ideation as endorsed by items 4 or 5 of the C-SSRS) or active suicidality requiring involuntary inpatient treatment or recent suicide attempts within the past month;
- Withdrawal, dropout, loss to follow-up, or demonstrated significant study intervention non-compliance of either the PSI-1V2 or Psilo-BD clinical trials.
Who the study is looking for
- Must be deemed to have capacity to provide informed consent;
- Must sign and date the informed consent form;
- Stated willingness to comply with all study procedures;
- Stated willingness to comply with group integration requirements (i.e., maintaining confidentiality of other group members and group etiquette);
- Stated willingness to commit to attending all group sessions. Of note, participants who miss a group session will not be penalized, provided they have communicated their anticipated or unanticipated absence with the study therapist(s);
- Ability to read and communicate in English, such that their literacy and comprehension is sufficient for understanding the consent form, study questionnaires and group participation, as evaluated by study staff obtaining consent;
- Met all the inclusion criteria and none of the exclusion criteria of either the PSI-1V2 or Psilo-BD clinical trials.
- Completed the Primary Endpoint measures as part of the PSI-1V2 or Psilo-BD clinical trials.
- Participants who are actively receiving therapy outside of this study are eligible to participate, provided the external therapy they are receiving is not psilocybin-assisted group integration psychotherapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Toronto Western Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.